TYK Medicines, Inc. Class H (HK:2410) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TYK Medicines, Inc. has reported an increased total comprehensive loss of 26.3% for the first half of 2024 compared to the same period last year, with significant rises in research and development costs and administrative expenses. The company’s losses per share also grew from RMB 0.60 to RMB 0.68, indicating a challenging period for the firm.
For further insights into HK:2410 stock, check out TipRanks’ Stock Analysis page.